These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 17595723)
1. FDA notifications. Enfuvirtide has new instructions. AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723 [No Abstract] [Full Text] [Related]
2. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor. AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478 [No Abstract] [Full Text] [Related]
6. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series. Polizzotto MN; Street AM; Wright E Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184 [TBL] [Abstract][Full Text] [Related]
7. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man. DeSimone JA; Ojha A; Pathak R; Cohn J Clin Infect Dis; 2004 Nov; 39(10):e110-2. PubMed ID: 15546072 [TBL] [Abstract][Full Text] [Related]
8. Enfurvirtide safety in human immunodeficiency virus-infected children. Baylor MS; Johann-Liang R Pediatr Infect Dis J; 2005 Apr; 24(4):389-90. PubMed ID: 15818309 [No Abstract] [Full Text] [Related]
9. Fusion inhibition--a major but costly step forward in the treatment of HIV-1. Tashima KT; Carpenter CC N Engl J Med; 2003 May; 348(22):2249-50. PubMed ID: 12773653 [No Abstract] [Full Text] [Related]
10. Acute hypersensitivity reaction to enfuvurtide upon re-challenge. Beilke MA Scand J Infect Dis; 2004; 36(10):778. PubMed ID: 15513412 [No Abstract] [Full Text] [Related]
11. [Fusion inhibitors. One year therapy with T-20--initial evaluation]. Goebel FD MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046 [No Abstract] [Full Text] [Related]
13. HIV infection--a new drug and new costs. Steinbrook R N Engl J Med; 2003 May; 348(22):2171-2. PubMed ID: 12773643 [No Abstract] [Full Text] [Related]